PRINCETON, N.J., Jan. 2, 2019 /PRNewswire/ -- Slayback Pharma LLC announced today that the U.S. Food and Drug Administration ("FDA") granted approval of its abbreviated new drug application ("ANDA") ...
pregnant pregnancy Hydroxyprogesterone Caproate is used to lower the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. American ...
MAKENA (hydroxyprogesterone caproate) 250mg/mL injection by Ther-Rx Corporation K-V Pharmaceutical Company announced today that the FDA and the Centers for Medicare & Medicaid Services (CMS) both ...
WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the U.S. Food and Drug Administration’s (FDA) Bone, Reproductive and Urologic Drugs Advisory ...
March 30, 2011 — Pharmacies can continue to compound generic hydroxyprogesterone caproate for reducing the risk for preterm delivery despite warnings from KV Pharmaceutical — which sells a costly, ...
WALTHAM, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today topline results from PROLONG (Progestin's Role in Optimizing Neonatal Gestation), a ...
Company Announces Collaboration With NurseWise(R) to Help Enhance Adherence to Makena(R) (hydroxyprogesterone caproate injection) Therapy WALTHAM, Mass., May 20, 2015 (GLOBE NEWSWIRE) -- AMAG ...
WALTHAM, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it received a notice from the U.S. Food and Drug Administration (FDA) that the FDA is ...
Federal health advisers recommended pulling Covis Pharma's preterm birth drug from the market because it has not been shown to be effective. The FDA's advisory panel voted 14-1 to withdraw Makena, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback